PHARMACEUTICAL PRODUCT DEVELOPMENT INC Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 29 rows, 29 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2011-12-05: Reporting owner Hill Raymond H; Form 4; Security Restricted Stock; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2011-12-05: Reporting owner Sharbaugh William J; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2011-12-05: Reporting owner Richardson William W; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2011-12-05: Reporting owner Wilkinson Michael O.; Form 4; Security Restricted Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2011-12-05 | Hill Raymond H Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Non-derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −30,000 0 owned after | no price filed | 2011-12-06 | |
| 2011-12-05 | Sharbaugh William J Officer (Chief Operating Officer) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −15,000 0 owned after | $0.00 | 2011-12-06 | |
| 2011-12-05 | Richardson William W Officer (Sr. VP Global Bus. Development) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,000 0 owned after | $0.00 | 2011-12-06 | |
| 2011-12-05 | Wilkinson Michael O. Officer (Chief Information Officer) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $0.00 | 2011-12-06 | |
| 2011-12-05 | HARTMAN JUDD Officer (General Counsel) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −15,000 0 owned after | $0.00 | 2011-12-06 | |
| 2011-12-05 | ESHELMAN FREDRIC N Director, Officer (Executive Chairman) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −30,000 0 owned after | $0.00 | 2011-12-06 | |
| 2011-12-05 | Dingivan Christine A Officer (EVP/Chief Medical Officer) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −15,000 0 owned after | $0.00 | 2011-12-06 | |
| 2011-12-05 | Darazsdi Daniel G Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −15,000 0 owned after | $0.00 | 2011-12-06 | |
| 2011-12-05 | COLVIN PAUL Officer (EVP--Clinical Development) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $0.00 | 2011-12-06 | |
| 2011-12-05 | Babiss Lee Officer (Exec. VP--Global Lab Services) | 4 | Restricted Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $0.00 | 2011-12-06 | |
| 2011-09-16 | Hill Raymond H Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Non-derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $0.00 | 2011-09-20 | |
| 2011-07-06 holding as of filing | Sharbaugh William J Officer (Chief Operating Officer) | 4 | Restricted Stock Units Derivative · Direct | Holding | 15,000 owned after | no price filed | 2011-07-06 | |
| 2011-07-06 holding as of filing | Richardson William W Officer (Sr. VP Global Bus. Development) | 4 | Restricted Stock Units Derivative · Direct | Holding | 5,000 owned after | no price filed | 2011-07-06 | |
| 2011-07-06 holding as of filing | Darazsdi Daniel G Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | Holding | 15,000 owned after | no price filed | 2011-07-06 | |
| 2011-07-06 holding as of filing | COLVIN PAUL Officer (EVP--Clinical Development) | 4 | Restricted Stock Units Derivative · Direct | Holding | 10,000 owned after | no price filed | 2011-07-06 | |
| 2011-05-27 holding as of filing | COLVIN PAUL Officer (EVP--Clinical Development) | 4 | Restricted Stock Units Derivative · Direct | Holding | 10,000 owned after | no price filed | 2011-05-27 | |
| 2011-05-23 holding as of filing | COLVIN PAUL Officer (EVP--Clinical Development) | 4 | Restricted Stock Units Derivative · Direct | Holding | 10,000 owned after | no price filed | 2011-05-23 | |
| 2011-05-19 holding as of filing | ESHELMAN FREDRIC N Director, Officer (Executive Chairman) | 4 | Restricted Stock Units Derivative · Direct | Holding | 30,000 owned after | no price filed | 2011-05-19 | |
| 2011-05-04 holding as of filing | HARTMAN JUDD Officer (General Counsel) | 4 | Restricted Stock Units Derivative · Direct | Holding | 15,000 owned after | no price filed | 2011-05-04 | |
| 2011-02-23 | Dingivan Christine A Officer (EVP/Chief Medical Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $0.00 | 2011-02-25 | |
| 2011-02-23 | Wilkinson Michael O. Officer (Chief Information Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $0.00 | 2011-02-25 | |
| 2011-02-23 | Sharbaugh William J Officer (Chief Operating Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $0.00 | 2011-02-25 | |
| 2011-02-23 | Richardson William W Officer (Sr. VP Global Bus. Development) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $0.00 | 2011-02-25 | |
| 2011-02-23 | HARTMAN JUDD Officer (General Counsel) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $0.00 | 2011-02-25 | |
| 2011-02-23 | ESHELMAN FREDRIC N Director, Officer (Executive Chairman) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $0.00 | 2011-02-25 | |
| 2011-02-23 | Darazsdi Daniel G Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $0.00 | 2011-02-25 | |
| 2011-02-23 | Darazsdi Daniel G Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $0.00 | 2011-02-25 | |
| 2011-02-23 | COLVIN PAUL Officer (EVP--Clinical Development) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $0.00 | 2011-02-25 | |
| 2011-02-23 | Babiss Lee Officer (Exec. VP--Global Lab Services) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $0.00 | 2011-02-25 |